These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 36342697)

  • 1. Probability of hospitalisation and death among COVID-19 patients with comorbidity during outbreaks occurring in Mexico City.
    Sifuentes-Osornio J; Angulo-Guerrero O; De Anda-Jáuregui G; Díaz-De-León-Santiago JL; Hernández-Lemus E; Benítez-Pérez H; Herrera LA; López-Arellano O; Revuelta-Herrera A; Rosales-Tapia AR; Suárez-Lastra M; Kershenobich D; Ruiz-Gutiérrez R
    J Glob Health; 2022 Nov; 12():05038. PubMed ID: 36342697
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Bayesian framework for estimating the risk ratio of hospitalization for people with comorbidity infected by SARS-CoV-2 virus.
    Gao X; Dong Q
    J Am Med Inform Assoc; 2021 Mar; 28(3):472-476. PubMed ID: 32986795
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Survival analysis and mortality predictors of COVID-19 in a pediatric cohort in Mexico.
    Solórzano-Santos F; Miranda-Lora AL; Márquez-González H; Klünder-Klünder M
    Front Public Health; 2022; 10():969251. PubMed ID: 36589967
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative epidemiology of five waves of COVID-19 in Mexico, March 2020-August 2022.
    Ascencio-Montiel IJ; Ovalle-Luna OD; Rascón-Pacheco RA; Borja-Aburto VH; Chowell G
    BMC Infect Dis; 2022 Oct; 22(1):813. PubMed ID: 36316634
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinico-demographic profile of COVID-19 positive patients - first wave versus second wave - an experience in north-east India.
    Kumar Prasad A; Bakorlin Khyriem A; Valarie Lyngdoh W; Jane Lyngdoh C; Chandra Phukan A; Kumar Bhattacharya P; Nongpiur V; Barman H; Baphira P; Sumitra Devi L; Gogoi N; Sapam S; Manisana Singh K; Bhattacharya S; Chakraborty S
    J Infect Dev Ctries; 2023 Feb; 17(2):166-177. PubMed ID: 36897893
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Survival among people hospitalized with COVID-19 in Switzerland: a nationwide population-based analysis.
    Anderegg N; Panczak R; Egger M; Low N; Riou J
    BMC Med; 2022 Apr; 20(1):164. PubMed ID: 35468785
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area.
    Richardson S; Hirsch JS; Narasimhan M; Crawford JM; McGinn T; Davidson KW; ; Barnaby DP; Becker LB; Chelico JD; Cohen SL; Cookingham J; Coppa K; Diefenbach MA; Dominello AJ; Duer-Hefele J; Falzon L; Gitlin J; Hajizadeh N; Harvin TG; Hirschwerk DA; Kim EJ; Kozel ZM; Marrast LM; Mogavero JN; Osorio GA; Qiu M; Zanos TP
    JAMA; 2020 May; 323(20):2052-2059. PubMed ID: 32320003
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical Characteristics and Mortality of Health-Care Workers With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection in Mexico City.
    Guerrero-Torres L; Caro-Vega Y; Crabtree-Ramírez B; Sierra-Madero JG
    Clin Infect Dis; 2021 Jul; 73(1):e199-e205. PubMed ID: 32986118
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Determinants of survival after severe acute respiratory syndrome coronavirus 2 infection in Mexican outpatients and hospitalised patients.
    Prado-Galbarro FJ; Sanchez-Piedra C; Gamiño-Arroyo AE; Cruz-Cruz C
    Public Health; 2020 Dec; 189():66-72. PubMed ID: 33166857
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
    Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
    Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
    [TBL] [Abstract][Full Text] [Related]  

  • 11. IMPACT OF COMORBIDITIES IN MEXICAN SARS-COV-2-POSITIVE PATIENTS: A RETROSPECTIVE ANALYSIS IN A NATIONAL COHORT.
    Kammar-García A; Vidal-Mayo JJ; Vera-Zertuche JM; Lazcano-Hernández M; Vera-López O; Segura-Badilla O; Aguilar-Alonso P; Navarro-Cruz AR
    Rev Invest Clin; 2020; 72(3):151-158. PubMed ID: 32584330
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SARS-CoV-2 infection fatality rate after the first epidemic wave in Mexico.
    Torres-Ibarra L; Basto-Abreu A; Carnalla M; Torres-Alvarez R; Reyes-Sanchez F; Hernández-Ávila JE; Palacio-Mejia LS; Alpuche-Aranda C; Shamah-Levy T; Rivera JA; Barrientos-Gutierrez T
    Int J Epidemiol; 2022 May; 51(2):429-439. PubMed ID: 35157072
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of pre-existing comorbidities with mortality and disease severity among 167,500 individuals with COVID-19 in Canada: A population-based cohort study.
    Ge E; Li Y; Wu S; Candido E; Wei X
    PLoS One; 2021; 16(10):e0258154. PubMed ID: 34610047
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness and cost-effectiveness of four different strategies for SARS-CoV-2 surveillance in the general population (CoV-Surv Study): a structured summary of a study protocol for a cluster-randomised, two-factorial controlled trial.
    Deckert A; Anders S; de Allegri M; Nguyen HT; Souares A; McMahon S; Boerner K; Meurer M; Herbst K; Sand M; Koeppel L; Siems T; Brugnara L; Brenner S; Burk R; Lou D; Kirrmaier D; Duan Y; Ovchinnikova S; Marx M; Kräusslich HG; Knop M; Bärnighausen T; Denkinger C
    Trials; 2021 Jan; 22(1):39. PubMed ID: 33419461
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Changes in the epidemiological profile of SARS-CoV-2-positive individuals in Mexico across pandemic waves as an explanation of fatality reduction: a retrospective observational study.
    Gutierrez JP; López D; Ascencio I; Juárez A; Olaiz G; Bertozzi SM
    BMJ Open; 2023 May; 13(5):e063211. PubMed ID: 37221025
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comorbidities associated with maternal mortality from COVID-19 in Mexico.
    López-Rodríguez G; Galván M; Valencia ÓG
    Gac Med Mex; 2021; 157(6):599-603. PubMed ID: 35108243
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk Factors for SARS-CoV-2 Infection, Pneumonia, Intubation, and Death in Northeast Mexico.
    Cordero-Franco HF; De La Garza-Salinas LH; Gomez-Garcia S; Moreno-Cuevas JE; Vargas-Villarreal J; González-Salazar F
    Front Public Health; 2021; 9():645739. PubMed ID: 34291023
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hypertension, Diabetes and Obesity, Major Risk Factors for Death in Patients with COVID-19 in Mexico.
    Peña JE; Rascón-Pacheco RA; Ascencio-Montiel IJ; González-Figueroa E; Fernández-Gárate JE; Medina-Gómez OS; Borja-Bustamante P; Santillán-Oropeza JA; Borja-Aburto VH
    Arch Med Res; 2021 May; 52(4):443-449. PubMed ID: 33380361
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of comorbidities and risk conditions on death from COVID-19 in migrants in Mexico.
    Martínez-Martínez OA; Valenzuela-Moreno KA; Coutiño B
    Int J Equity Health; 2021 Dec; 20(1):257. PubMed ID: 34922533
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical, demographical characteristics and hospitalisation of 3,010 patients with Covid-19 in Friuli Venezia Giulia Region (Northern Italy). A multivariate, population-based, statistical analysis.
    Gobbato M; Clagnan E; Burba I; Rizzi L; Grassetti L; Del Zotto S; Dal Maso L; Serraino D; Tonutti G
    Epidemiol Prev; 2020; 44(5-6 Suppl 2):226-234. PubMed ID: 33412814
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.